Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria

被引:51
作者
Zechmeister, Ingrid [1 ]
de Blasio, Birgitte Freiesleben [2 ]
Garnett, Geoff [3 ]
Neilson, Aileen Rae [4 ]
Siebert, Uwe [5 ,6 ,7 ,8 ]
机构
[1] Ludwig Boltzmann Inst Hlth Technol Assessment, A-1090 Vienna, Austria
[2] Univ Oslo, Inst Basic Med Sci, Oslo, Norway
[3] Univ London Imperial Coll Sci Technol & Med, Inst Microparasite Epidemiol, London, England
[4] Norwegian Knowledge Ctr Hlth Serv, Oslo, Norway
[5] Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth Med Decis Making & HTA, Hall In Tirol, LT, Austria
[6] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Decis Sci, Boston, MA 02115 USA
[7] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Inst Technol Assessment, Boston, MA USA
[8] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA
关键词
HPV-vaccination; Cost-effectiveness; Cervical cancer screening; ECONOMIC-EVALUATION; HPV VACCINATION; NATURAL-HISTORY; MODEL; TRANSFERABILITY; INFECTION; HEALTH; IMPACT; WOMEN;
D O I
10.1016/j.vaccine.2009.06.039
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: The study predicts long-term cervical cancer related population health and economic effects of introducing the HPV-vaccination for 12-year-old girls (and boys) in addition to current screening compared with screening only. Method: Health effects are predicted by a dynamic transmission model. Model results are used to calculate incremental cost-effectiveness ratios (ICER) in (sic) per life year gained (LYG) for a time-horizon between 2008 and 2060 from a public payer and a societal perspective. Results: Vaccination of girls results a discounted ICER of (sic) 64,000/LYG and (sic) 50,000/LYG from a payer's and societal perspectives respectively. The additional vaccination of boys increases the ICER to (sic) 311,000 and (sic) 299,000/LYG respectively. Results were most sensitive to vaccination price, discount rate and time-horizon. Conclusion: HPV-vaccination for girls should be cost-effective when adopting a longer time-horizon and a societal perspective. Applying a shorter time frame and a payer's perspective or vaccinating boys may not be cost-effective without reducing the vaccine price. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5133 / 5141
页数:9
相关论文
共 50 条
  • [41] Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands
    Tjalke A Westra
    Irina Stirbu-Wagner
    Sara Dorsman
    Eric D Tutuhatunewa
    Edwin L de Vrij
    Hans W Nijman
    Toos Daemen
    Jan C Wilschut
    Maarten J Postma
    [J]. BMC Infectious Diseases, 13
  • [42] The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands
    Bogaards, Johannes A.
    Coupe, Veerle M. H.
    Meijer, Chris J. L. M.
    Berkhof, Johannes
    [J]. VACCINE, 2011, 29 (48) : 8929 - 8936
  • [43] Increasing HPV vaccination coverage to prevent oropharyngeal cancer: A cost-effectiveness analysis
    Choi, Sung Eun
    Choudhary, Abhishek
    Huang, Jingyi
    Sonis, Stephen
    Giuliano, Anna R.
    Villa, Alessandro
    [J]. TUMOUR VIRUS RESEARCH, 2022, 13
  • [44] Cost-effectiveness of human papillomavirus (HPV) vaccination in Burkina Faso: a modelling study
    Kiendrebeogo, Joel Arthur
    Sidibe, Annick Raissa O.
    Compaore, Ghislain Bertrand
    Nacanabo, Relwende
    Sory, Orokia
    Ouedraogo, Issa
    Nawaz, Saira
    Schuind, Anne E.
    Clark, Andrew
    [J]. BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [45] Cost-effectiveness of the vaccine against human papillomavirus in the Brazilian Amazon region
    da Fonseca, Allex Jardim
    de Lima Ferreira, Luiz Carlos
    Balbinotto Neto, Giacomo
    [J]. REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2013, 59 (05): : 442 - 451
  • [46] Adjuvant Human Papillomavirus Vaccination After Excisional Procedure for Cervical Intraepithelial Neoplasia A Cost-Effectiveness Analysis
    Chaiken, Sarina R.
    Bruegl, Amanda S.
    Caughey, Aaron B.
    Emerson, Jenna
    Munro, Elizabeth G.
    [J]. OBSTETRICS AND GYNECOLOGY, 2023, 141 (04) : 756 - 763
  • [47] Cost-effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in Quebec, Canada
    Vijayaraghavan, Arthi
    Efrusy, Molly B.
    Mayrand, Marie-Helene
    Santas, Christopher C.
    Goggin, Patricia
    [J]. CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 2010, 101 (03): : 220 - 225
  • [48] Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing
    van Rosmalen, J.
    de Kok, I. M. C. M.
    van Ballegooijen, M.
    [J]. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2012, 119 (06) : 699 - 709
  • [49] Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands
    Simons, Joost J. M.
    Vida, Nora
    Westra, Tjalke A.
    Postma, Maarten J.
    [J]. VACCINE, 2020, 38 (30) : 4687 - 4694
  • [50] Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: Adaptation of an existing cohort model to the situation in the Netherlands
    Rogoza, R. M.
    Westra, T. A.
    Ferko, N.
    Tamminga, J. J.
    Drummond, M. F.
    Daemen, T.
    Wilschut, J. C.
    Postma, M. J.
    [J]. VACCINE, 2009, 27 (35) : 4776 - 4783